Tags : budesonide

AstraZeneca Reports Results of PT027 (albuterol and budesonide) in P-III

Tuba Khan September 9, 2021

Shots: The P-III MANDALA & DENALI trial evaluates the efficacy & safety of PT027 (180/160mcg & 180/80mcg doses) vs albuterol & albuterol and budesonide aged ≥4yrs. in 3132 & 1001 […]readmore

MedTech Pharma

AstraZeneca Reports Results of Symbicort Turbuhaler (budesonide/formoterol) in Novel START

Tuba Khan May 21, 2019

Shots: The Novel START study results involve assessing of Symbicort Turbuhaler (prn) vs Albuterol (prn) or Budesonide (ICS maintenance treatment) + albuterol (prn) in 668 patients with mild asthma aged […]readmore

Tags : budesonide

AstraZeneca Reports Results of PT027 (albuterol and budesonide) in P-III

AstraZeneca Reports Results of Symbicort Turbuhaler (budesonide/formoterol) in Novel START

Latest Posts

PharmaShots Weekly Snapshots (November 15 – 19, 2021)

Jazz’ Sunosi (solriamfetol) Receives NICE Recommendation for the Treatment of Excessive Daytime Sleepiness Caused by Narcolepsy

Antengene’s Selinexor (ATG-010) Receives NMPA’s IND Approval for P-I/II SWATCH Study to Treat Non-Hodgkin Lymphoma

Daiichi Sankyo Reports Results of Quizartinib in P-III QuANTUM-First Trial for the Treatment of FLT3-ITD Positive AML

Company

Tags : budesonide

AstraZeneca Reports Results of PT027 (albuterol and budesonide) in P-III

AstraZeneca Reports Results of Symbicort Turbuhaler (budesonide/formoterol) in Novel START

Latest Posts

PharmaShots Weekly Snapshots (November 15 – 19, 2021)

Jazz’ Sunosi (solriamfetol) Receives NICE Recommendation for the Treatment of Excessive Daytime Sleepiness Caused by Narcolepsy

Antengene’s Selinexor (ATG-010) Receives NMPA’s IND Approval for P-I/II SWATCH Study to Treat Non-Hodgkin Lymphoma

Daiichi Sankyo Reports Results of Quizartinib in P-III QuANTUM-First Trial for the Treatment of FLT3-ITD Positive AML

Categories

Related Topics

Company